



## Horizon Therapeutics plc to Release First-Quarter 2022 Financial Results and Host Webcast on May 4, 2022

April 14, 2022

DUBLIN--(BUSINESS WIRE)--Apr. 14, 2022-- Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it will release its first-quarter 2022 financial results on Wednesday, May 4, 2022. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results.

The live webcast and a replay may be accessed at <http://ir.horizontherapeutics.com>. Please connect to the Company's website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. A replay of the webcast will be available approximately two hours after the live webcast.

### About Horizon

Horizon is focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: We apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, visit [www.horizontherapeutics.com](http://www.horizontherapeutics.com) and follow us on [Twitter](#), [LinkedIn](#), [Instagram](#) and [Facebook](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220413006001/en/): <https://www.businesswire.com/news/home/20220413006001/en/>

### Horizon Contact:

Tina Ventura  
Senior Vice President, Chief Investor Relations Officer  
[investor-relations@horizontherapeutics.com](mailto:investor-relations@horizontherapeutics.com)

### U.S. Media Contact:

Geoff Curtis  
Executive Vice President, Corporate Affairs & Chief Communications Officer  
[media@horizontherapeutics.com](mailto:media@horizontherapeutics.com)

### Ireland Media Contact:

Gordon MRM  
Ray Gordon  
[ray@gordonmrm.ie](mailto:ray@gordonmrm.ie)

Source: Horizon Therapeutics plc